US FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)

By
Ishira
-
0
344
Bayer announced the US FDA has accepted a sNDA and granted Priority Review for the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of mHSPC.
[Bayer AG]
Press Release